These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 25993203)

  • 61. Towards personalized treatment for early stage HER2-positive breast cancer.
    Goutsouliak K; Veeraraghavan J; Sethunath V; De Angelis C; Osborne CK; Rimawi MF; Schiff R
    Nat Rev Clin Oncol; 2020 Apr; 17(4):233-250. PubMed ID: 31836877
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer.
    Alvarez RH; Hortobagyi GN
    Breast Cancer; 2013 Apr; 20(2):103-10. PubMed ID: 23377763
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Optimal Management of Early and Advanced HER2 Breast Cancer.
    Hurvitz SA; Gelmon KA; Tolaney SM
    Am Soc Clin Oncol Educ Book; 2017; 37():76-92. PubMed ID: 28561711
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Recent Updates on the Therapeutic Potential of HER2 Tyrosine Kinase Inhibitors for the Treatment of Breast Cancer.
    Singla H; Munshi A; Banipal RPS; Kumar V
    Curr Cancer Drug Targets; 2018; 18(4):306-327. PubMed ID: 28669349
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Current approaches and future directions in the treatment of HER2-positive breast cancer.
    Hurvitz SA; Hu Y; O'Brien N; Finn RS
    Cancer Treat Rev; 2013 May; 39(3):219-29. PubMed ID: 22658319
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Should patients with HER2 loss after neoadjuvant treatment still be treated with adjuvant trastuzumab treatment?
    Altundag K
    J BUON; 2017; 22(4):1085. PubMed ID: 28952236
    [No Abstract]   [Full Text] [Related]  

  • 67. The management of HER2-positive early breast cancer: Current and future therapies.
    Chen J; Colosimo M; Lim E
    Asia Pac J Clin Oncol; 2021 Sep; 17 Suppl 6():3-12. PubMed ID: 34490737
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Biomarkers for Predicting Response to Anti-HER2 Agents.
    Varadan V; Sandoval M; Harris LN
    Adv Exp Med Biol; 2016; 882():155-67. PubMed ID: 26987534
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Systemic treatment of HER2-positive metastatic breast cancer: a systematic review.
    Wilcken N; Zdenkowski N; White M; Snyder R; Pittman K; Mainwaring P; Green M; Francis P; De Boer R; Colosimo M; Chua S; Chirgwin J; Beith J; Bell R
    Asia Pac J Clin Oncol; 2014 Jun; 10 Suppl S4():1-14. PubMed ID: 24797445
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Optimizing Treatment of HER2-Positive Breast Cancer.
    Gradishar WJ
    J Natl Compr Canc Netw; 2015 May; 13(5 Suppl):649-51. PubMed ID: 25995420
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Lessons from breast cancer trials of HER2-kinase inhibitors.
    Krop IE
    Lancet Oncol; 2016 Mar; 17(3):267-268. PubMed ID: 26822399
    [No Abstract]   [Full Text] [Related]  

  • 72. Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients.
    Singh JC; Lichtman SM
    Drugs Aging; 2021 Oct; 38(10):829-844. PubMed ID: 34423398
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer.
    Dent SF; Morse A; Burnette S; Guha A; Moore H
    Curr Oncol Rep; 2021 Aug; 23(11):128. PubMed ID: 34453232
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Systemic Treatments in Pregnancy-Associated Breast Cancer.
    Tehrani OS
    Adv Exp Med Biol; 2020; 1252():115-124. PubMed ID: 32816270
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Metastatic HER2-Positive Breast Cancer: Tailoring Treatment Un-'TIL' We Get It Right..
    Jankowitz RC; Rastogi P
    Oncology (Williston Park); 2016 Feb; 30(2):156, 158-9. PubMed ID: 26892152
    [No Abstract]   [Full Text] [Related]  

  • 76. HER2 positive breast cancer patients having HER2 loss after neoadjuvant chemotherapy should still be treated with adjuvant anti-HER2 treatment.
    Altundag K
    Breast Cancer Res Treat; 2019 May; 175(1):261. PubMed ID: 30707335
    [No Abstract]   [Full Text] [Related]  

  • 77. Role of Anti-HER-2 Therapies in the Neo-Adjuvant Setting: Is Complete Pathological Response a Solid Surrogate?
    Valsecchi ME; Díaz-Cantón E
    Rev Recent Clin Trials; 2015; 10(2):82-9. PubMed ID: 26216436
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The role of neoadjuvant (HER)2-targeted therapies in (HER)2-overexpressing breast cancers.
    Lemieux J; Clemons M; Provencher L; Dent S; Latreille J; Mackey J; Pritchard KI; Rayson D; Verma Sh; Verma S; Wang B; Chia S
    Curr Oncol; 2009 Sep; 16(5):48-57. PubMed ID: 19862361
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Targeted therapy for HER2 positive breast cancer.
    Incorvati JA; Shah S; Mu Y; Lu J
    J Hematol Oncol; 2013 Jun; 6():38. PubMed ID: 23731980
    [TBL] [Abstract][Full Text] [Related]  

  • 80. HER2-positive breast cancer is lost in translation: time for patient-centered research.
    Gingras I; Gebhart G; de Azambuja E; Piccart-Gebhart M
    Nat Rev Clin Oncol; 2017 Nov; 14(11):669-681. PubMed ID: 28762384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.